CyberKnife® treatments, with sub-millimeter accuracy and highly conformal dosimetry, was the only reasonable option to control the patient’s tumor without causing undue radiation-induced toxicity.
A PROVEN STEREOTACTIC RADIOSURGERY PLATFORM. QUALITY OUTCOMES.
CyberKnife’s precise delivery allows the expansion of stereotactic radiosurgery and stereotactic body radiation therapy treatments to indications not possible to treat on any other radiation therapy machine.
Due to the tumor location, stereotactic radiosurgery (SRS) was indicated in favor of surgery. The patient proactively inquired six months prior regarding the possibility of
The use of the CyberKnife System allows a clinician to perform accurate treatment because of its capability to track the tumor throughout treatment.
The CyberKnife System provided a convenient and minimally invasive treatment option for patients with metastasis to para-aortic lymph nodes.
Treatment with CyberKnife radiosurgery utilizing a hypofractionated treatment regimen was indicated for maximum local control and to minimize injury to the optic apparatus.
Three months after treatment, the patient reported no evidence of local regional recurrence or treatment-related toxicity.
This patient had an excellent initial outcome with the CyberKnife System using Xsight® Lung Tracking; the patient was able to undergo treatment without implanted fiducials
Due to the risk of recurrence and intimate association of the lesion with the optic nerve, the CyberKnife® System was selected.
There were no further treatment possibilities as surgery, conventional radiation therapy and chemotherapy were already attempted without preventing tumor growth.
The treatment of both malignant as well as benign tumors of the spine using CyberKnife radiosurgery began in 1997. Treatment of spine lesions using single